Literature DB >> 30394807

Diabetes Technology Society Report on the FDA Digital Health Software Precertification Program Meeting.

Fraya King1, David C Klonoff1, David Ahn2, Saleh Adi3, Erika Gebel Berg4, Jiang Bian5, Kong Chen6, Andjela Drincic7, Michael Heyl8, Michelle Magee9, Shelagh Mulvaney10, Yarmela Pavlovic11, Priya Prahalad12, Michael Ryan13, Ashutosh Sabharwal14, Shahid Shah15, Elias Spanakis16, Bradley Merrill Thompson17, Michael Thompson3, Jing Wang18.   

Abstract

Diabetes Technology Society (DTS) convened a meeting about the US Food and Drug Administration (FDA) Digital Health Software Precertification Program on August 28, 2018. Forty-eight attendees participated from clinical and academic endocrinology (both adult and pediatric), nursing, behavioral health, engineering, and law, as well as representatives of FDA, National Institutes of Health (NIH), National Telecommunications and Information Administration (NTIA), and industry. The meeting was intended to provide ideas to FDA about their plan to launch a Digital Health Software Precertification Program. Attendees discussed the four components of the plan: (1) excellence appraisal and certification, (2) review pathway determination, (3) streamlined premarket review process, and (4) real-world performance. The format included (1) introductory remarks, (2) a program overview presentation from FDA, (3) roundtable working sessions focused on each of the Software Precertification Program's four components, (4) presentations reflecting the discussions, (5) questions to and answers from FDA, and (6) concluding remarks. The meeting provided useful information to the diabetes technology community and thoughtful feedback to FDA.

Entities:  

Keywords:  FDA precertification; device; real-world data; software

Mesh:

Year:  2018        PMID: 30394807      PMCID: PMC6313279          DOI: 10.1177/1932296818810436

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  2 in total

1.  New Opportunities for Digital Health to Thrive.

Authors:  David C Klonoff; Fraya King; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2019-01-24

2.  Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes.

Authors:  David C Klonoff; Alberto Gutierrez; Alexander Fleming; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2019-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.